News

A company-sponsored study found that Theranica’s digital therapeutic Nerivio resulted in a substantial reduction in intake of prescribed pharmacological medications

Court challenges on the independent dispute resolution process. A district court judge has vacated that part of the law nationwide.

But there is no significant difference in rate of hospitalization for major bleeding when Eliquis is compared with Xarelto or warfarin.

In this first of a two-part video series, Jason Warrelmann, global director of Healthcare and Life Sciences at UiPath, addressed the incline of automation in healthcare, why it's necessary for patients and providers and how other healthcare organizations can better overcome the challenges of adopting automation within their health system.

Five years ago, health care providers didn’t see mobile as a priority or a necessary tool in improving the patient experience. The pandemic changed that.

FDA approves first generic of Symbicort for asthma and COPD and first therapy for rare seizure disorder, Rinvoq and Lynparza get nods for new indications, the agency approves a new delivery system for Alzheimer’s therapy, regulators extend review for Opzelura for skin condition and issue CRL for Fasenra for chronic rhinosinusitis.

A recent survey found COVID-19 death rates among both Black and white individuals were higher in areas with more residential segregation, with Black individuals’ death rates being almost twice as high.

Del Doherty, co-founder of Prodigy Rx, discusses how the PBM aims to give payers control so they can lower costs and can improve clinical and return-to-work outcomes.

Amneal is of 35 global companies selected to manufacture and commercialize generic version of COVID-19 treatment Paxlovid.

William Dietz, MD, PhD, Professor and Director of Sumner M. Redstone Global Center for Prevention and Wellness at George Washington University, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.

New data show longer-term benefits from Aduhelm, which was approved last year to treat Alzheimer’s disease.

ICER analyzed two therapies — Cosela and plinabulin — to prevent chemotherapy-induced neutropenia and other myelosuppressive effects. Both moderately increased quality-adjusted life-years.

ICER also reviewed, plinabulin, which is development chemotherapy-induced neutropenia (CIN) and would achieve common thresholds for cost-effectiveness if priced between $1,100 and $1,600 per dose.

Aaron Glatt, MD, Chairman of the Department of Medicine and Chief of Infectious Diseases/Hospital Epidemiologist at Mount Sinai South Nassau and Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.

The toll that Alzheimer’s disease takes on the health of those affected by the disease is enormous. And so is the associated expense.

There’s no guarantee, but physical activity and corralling cardiovascular risk factors and diabetes improve the odds. Health insurers can assist by helping members address the “upstream” social determinants of health.

In this week's episode, Briana Contreras, editor of Managed Healthcare Executive, spoke with Peter Durlach, chief strategy officer of Nuance. The two discussed how artificial intelligence drives value for patients and providers and how AI tools and solutions are helping health systems reach the quadruple aim of care.

Their application to the FDA included data showing that confirmed infections and severe illness were lower among individuals who received a second booster of the Pfizer-BioNTech vaccine.

Allan Coukell, Civica’s senior vice president of public policy, discusses how the generic manufacturer is disrupting the market for insulins.

A Johns Hopkins study found an association between use of e-cigarettes and prediabetes. More research is needed to tease out the possible causal elements of the association. Meanwhile, a federal government survey found that 1.72 million high school students and 320,000 middle schoolers are current users of e-cigarettes.

Evio Pharmacy Solutions plans to provide biosimilar alternatives for autoimmune and cancer therapeutics.

The American Cancer Society’s 2022 statistical report shows that the 30-year trend is continuing.

Saunders, co-founder at Intellihealth and assistant professor of Clinical Medicine at Weill Cornell Medical College, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.

In an interim analysis, Keytruda/Lynparza did not improve overall survival in patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy.

Research presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting found minority patients with asthma perceived lower quality interactions with their care team, but did not find significant differences in the prescription of biologic medications across racial/ethnic groups.

Voluntary guidelines passed in January show a way to making interoperability work on a practical level.

Home healthcare is booming, and precision medicine is going to create a demand for employees with new kinds of expertise. But people working in the healthcare are also likely to see growth in internal promotions, specifically for cross-collaboration and cross-functional roles.

A recently published review delves into the role that type 2 inflammation plays chronic rhinosinusitis and the evidence that agents that interfere with that inflammatory pathway could be used as treatments.